ALDH18A1-Related Autosomal Dominant Cutis Laxa Type 3

1. Disease Information

Overview

Autosomal Dominant Cutis Laxa Type 3 (ADCL3) is a rare genetic connective tissue disorder characterized by loose, redundant, inelastic skin giving a prematurely aged (progeroid) appearance, combined with multisystem involvement including growth restriction, developmental delay, cataracts, and vascular abnormalities. The condition belongs to the broader group of cutis laxa syndromes—a clinically and genetically heterogeneous set of diseases unified by defective elastic fiber formation or maintenance (PMID: 23954411).

ADCL3 was first formally delineated in 2015 by Fischer-Zirnsak et al., who identified recurrent de novo mutations at the highly conserved Arg138 residue of P5CS in eight unrelated individuals previously diagnosed with De Barsy syndrome or wrinkly skin syndrome (PMID: 26320891). The condition overlaps phenotypically with the autosomal recessive form of cutis laxa type 3A (ARCL3A, caused by biallelic ALDH18A1 mutations) but is distinguished by its de novo dominant-negative mechanism.

Key Identifiers

Synonyms and Alternative Names

• Autosomal dominant cutis laxa type 3 (ADCL3)
• ADCL3
• Cutis laxa, autosomal dominant, type 3
• De Barsy-like progeroid syndrome (historical, before genetic delineation)
• ALDH18A1-related autosomal dominant cutis laxa
• P5CS deficiency, autosomal dominant cutis laxa form
• Progeroid form of autosomal dominant cutis laxa

Information Source

The information in this report is derived from aggregated disease-level resources including OMIM, Orphanet, ClinVar, and primary literature (PubMed), as well as individual case reports. No EHR-based data were used.

2. Etiology

Disease Causal Factors

ADCL3 is a monogenic disorder caused by heterozygous de novo missense mutations in ALDH18A1 (10q24.1), encoding the mitochondrial enzyme P5CS. The disease mechanism is dominant-negative: the mutant protein is stable, incorporates into oligomeric complexes with wild-type P5CS, but disrupts normal complex assembly and sub-mitochondrial distribution, leading to reduced enzymatic activity (PMID: 26320891).

The key causal chain is: 1. De novo missense mutation in ALDH18A1 (typically in the glutamate 5-kinase [G5K] domain) 2. Mutant P5CS protein produced, stable, but with altered conformation 3. Mutant protein interacts with wild-type P5CS in oligomeric complexes 4. Disrupted complex formation and altered sub-mitochondrial localization 5. Reduced P5CS enzymatic activity 6. Impaired de novo biosynthesis of proline and ornithine from glutamate 7. Proline deficiency leads to impaired collagen/elastin synthesis (skin laxity, connective tissue dysfunction) 8. Ornithine/citrulline/arginine pathway disruption affects urea cycle function 9. Mitochondrial metabolic dysfunction contributes to neurodegeneration

Risk Factors

Genetic Risk Factors

• De novo mutations in ALDH18A1: All confirmed ADCL3 cases arise from spontaneous germline mutations. No inherited predisposition has been identified, and affected individuals are typically born to unaffected, non-consanguineous parents (PMID: 26320891; PMID: 28228640; PMID: 40164711).
• Mutational hotspot: The Arg138 residue represents a recurrent mutation site, suggesting a potential CpG dinucleotide-related mechanism for recurrent de novo mutation.
• There are no known genetic susceptibility loci, modifier genes, or GWAS associations for this ultra-rare Mendelian condition.

Environmental Risk Factors

• No environmental risk factors have been identified. The disease is entirely genetic in origin.
• Advanced paternal age may theoretically increase de novo mutation risk, as is common for autosomal dominant de novo conditions, but this has not been specifically studied for ADCL3.

Protective Factors

No genetic or environmental protective factors have been identified for ADCL3.

Gene-Environment Interactions

No gene-environment interactions have been described. However, nutritional status may modulate disease severity: - One case report described features mimicking refractory rickets with severely low vitamin D levels, suggesting that nutritional deficiencies may compound the clinical presentation (PMID: 40018427). - Theoretically, dietary proline intake could influence the severity of proline deficiency, but this has not been formally studied.

3. Phenotypes

Core Phenotypic Features

ADCL3 presents as a multisystem disorder with the following major phenotypic categories:

Integumentary (Skin and Connective Tissue)

Musculoskeletal

Neurological

Neuroimaging findings were carefully characterized: "One patient had intracranial arterial and venous tortuosity, widened ventricular and extra-axial cerebrospinal fluid (CSF) spaces, wide perivascular spaces and increased T2 signal intensity in the cerebral white matter over time" (PMID: 28757335).

Ophthalmological

Growth

Craniofacial/Dysmorphic Features

Vascular

A comprehensive case description captures the full phenotype: "We report a novel case of ADCL in a 1.6-year-old patient presenting with growth delay, hypotonia, joint laxity, lax skin, cataract, dysmorphic features, microcephaly, cranial vessel tortuosity, hip dislocation, and psychomotor retardation" (PMID: 40164711).

Quality of Life Impact

ADCL3 severely impacts quality of life across multiple domains: - Physical functioning: Profound motor delays, hypotonia, and joint abnormalities limit mobility and independence - Cognitive functioning: Most patients have moderate-to-severe intellectual disability affecting all aspects of daily living - Social participation: Progeroid appearance and developmental delays significantly impact social integration - Caregiver burden: Patients require lifelong intensive care and support - No formal quality of life studies (e.g., EQ-5D, SF-36) have been conducted in this ultra-rare population.

4. Genetic/Molecular Information

Causal Gene

• Gene: ALDH18A1 (Aldehyde Dehydrogenase 18 Family Member A1)
• HGNC ID: HGNC:360
• OMIM Gene: 138250
• Ensembl: ENSG00000059573
• NCBI Gene ID: 5832
• Chromosomal location: 10q24.1
• Protein: Delta-1-pyrroline-5-carboxylate synthase (P5CS)
• UniProt: P54886

P5CS is "a bifunctional ATP- and NADPH-dependent mitochondrial enzyme [that] catalyzes the reduction of glutamate to delta(1)-pyrroline-5-carboxylate, a critical step in the biosynthesis of proline, ornithine and arginine" (PMID: 11092761). Two isoforms exist from alternative splicing: a short isoform (expressed in gut, involved in arginine biosynthesis, ornithine-inhibited) and a long isoform (expressed in multiple tissues, involved in proline synthesis, ornithine-insensitive).

Pathogenic Variants

All confirmed ADCL3-causing variants are heterozygous de novo missense mutations in the glutamate 5-kinase (G5K) domain of P5CS:

Key characteristics: - Variant type: All are missense substitutions - Origin: All confirmed de novo (germline); "A de novo origin was confirmed in all six probands for whom parental DNA was available" (PMID: 26320891) - Allele frequency: Absent from population databases (gnomAD, ExAC, 1000 Genomes) consistent with severe de novo condition - Functional consequence: Dominant-negative effect — "the P5CS-p.Arg138Trp protein was stable and able to interact with wild-type P5CS but showed an altered sub-mitochondrial distribution. A reduced size upon native gel electrophoresis indicated an alteration of the structure or composition of P5CS mutant complex" (PMID: 26320891) - Hotspot: Arg138 is the most commonly affected residue with three different substitutions documented

The mutational spectrum was expanded by Bhola et al. (2017): "This is the first report of an individual with ALDH18A1-ADCL due to a substitution at a residue other than p.Arg138" (PMID: 28228640), and further by Ahmad et al. (2025): "This variant has not been previously reported, and it is the first report of an individual with ALDH18A1-ADCL due to a substitution at a highly conserved residue, p.Ser134 of the P5CS protein" (PMID: 40164711).

Distinction from Related ALDH18A1 Disorders

ALDH18A1 mutations cause a spectrum of four distinct but overlapping conditions (PMID: 32798076):

"ALDH18A1-related disorders have been classified into four groups, such as autosomal dominant and recessive hereditary spastic paraplegia (SPG9A and SPG9B, respectively), as well as autosomal dominant and recessive cutis laxa (ADCL3 and ARCL3A, respectively). Neurodegeneration is a characteristic feature of all groups" (PMID: 32798076).

Genotype-Phenotype Correlations

A critical observation is the domain-specific effect on biochemistry: "Mutations affecting the G5K domain have previously been found to cause reduced plasma levels of proline, citrulline and arginine, whereas such effect is not seen with mutations affecting the GR5P domain" (PMID: 29754261). Since all ADCL3 mutations affect the G5K domain, amino acid abnormalities are expected though not invariably present.

Intrafamilial clinical variability has been noted in SPG9A families with the same ALDH18A1 mutation, suggesting potential modifier effects (PMID: 33573605).

Modifier Genes

No modifier genes have been formally identified. PYCR1 and PYCR2 (downstream enzymes in proline biosynthesis) could theoretically modify severity, and variation in proline transport genes may contribute to phenotypic variability.

Epigenetic Information

No epigenetic modifications specific to ADCL3 have been reported. The recurrence of Arg138 mutations may be related to CpG dinucleotide methylation-mediated deamination at the DNA level.

Chromosomal Abnormalities

ADCL3 is not associated with chromosomal abnormalities. All causative variants are single nucleotide substitutions.

5. Environmental Information

Environmental Factors

No environmental factors are known to cause or contribute to ADCL3. The disease is entirely monogenic.

Lifestyle Factors

No lifestyle factors have been identified as contributing to disease onset. However, nutritional status may influence disease severity, particularly vitamin D levels—one case presented with features mimicking refractory rickets (PMID: 40018427). Dietary proline intake could theoretically modulate proline availability, but this has not been formally studied.

Infectious Agents

Not applicable. ADCL3 is not caused by or associated with infectious agents.

6. Mechanism / Pathophysiology

Molecular Pathways

ADCL3 pathophysiology centers on disruption of the proline-ornithine biosynthetic pathway from glutamate:

Glutamate → [P5CS/G5K: γ-glutamyl phosphate] → [P5CS/G5PR: GSA] → P5C
                                                      ↓
                                            ┌─────────┴──────────┐
                                            ↓                    ↓
                                     Proline (via PYCR)    Ornithine (via OAT)
                                                                 ↓
                                                           Citrulline → Arginine

KEGG Pathway: Arginine and proline metabolism (hsa00330) Reactome: Metabolism of amino acids and derivatives (R-HSA-71291)

The key metabolic consequences of P5CS deficiency include: 1. Impaired proline biosynthesis: Proline is essential for collagen synthesis (~25% of collagen amino acids are proline/hydroxyproline). Reduced proline availability impairs collagen and elastin production 2. Impaired ornithine biosynthesis: Ornithine is a key intermediate in the urea cycle; deficiency leads to reduced citrulline and arginine levels 3. Disrupted mitochondrial redox homeostasis: The proline-P5C cycle serves as a redox shuttle between the cytosol and mitochondria

Dominant-Negative Mechanism

P5CS functions as a homo-oligomeric complex that forms filamentous structures (PMID: 35286254). In ADCL3, the mutant P5CS protein:

1. Is stably expressed — not degraded by protein quality control
2. Incorporates into wild-type complexes — physically interacts with normal P5CS
3. Disrupts complex architecture — altered size on native gel electrophoresis
4. Mislocalizes within mitochondria — altered sub-mitochondrial distribution
5. Reduces enzymatic activity — delayed proline accumulation in patient fibroblasts

This "poison subunit" mechanism is more severe than haploinsufficiency, explaining why heterozygous carriers of loss-of-function alleles (carriers in AR families) are typically unaffected, while ADCL3 patients with dominant-negative alleles are severely affected.

Cellular Processes

• Extracellular matrix assembly (GO:0085029): Impaired collagen and elastin fiber assembly due to proline deficiency
• Mitochondrial metabolism (GO:0006099): Disrupted mitochondrial proline-P5C cycling affecting NADH/NAD+ balance
• Urea cycle (GO:0000050): Secondary disruption via reduced ornithine availability
• Protein folding: Proline is critical for collagen triple helix stability
• Redox homeostasis (GO:0045454): The proline cycle links cytosolic NADPH oxidation to mitochondrial electron transport

Protein Dysfunction

The P5CS protein (UniProt: P54886) contains two functional domains: - Glutamate 5-kinase (G5K) domain (N-terminal): Phosphorylates glutamate to gamma-glutamyl phosphate - Gamma-glutamyl phosphate reductase (G5PR) domain (C-terminal): Reduces gamma-glutamyl phosphate to glutamate-γ-semialdehyde

All ADCL3 mutations cluster in the G5K domain (residues 126–138), which is critical for the dominant-negative interaction. The structural basis involves disruption of the filamentous oligomeric assembly of P5CS, as revealed by cryo-EM studies (PMID: 35286254).

Metabolic Changes

Patients with G5K domain mutations show: - Reduced plasma proline (CHEBI:26271) - Reduced plasma ornithine (CHEBI:15729) - Reduced plasma citrulline (CHEBI:18211) - Reduced plasma arginine (CHEBI:29016)

These amino acid abnormalities were documented across ALDH18A1-related disorders: "Low levels of plasma ornithine, citrulline, arginine and proline in four individuals from two families suggested P5CS deficiency" (PMID: 26026163). However, amino acid levels may be normal in some cases depending on mutation location and dietary intake (PMID: 29754261).

Tissue Damage Mechanisms

1. Connective tissue: Proline deficiency impairs collagen synthesis, leading to defective elastic fiber assembly in skin, blood vessels, and connective tissues. The cutis laxa phenotype reflects impaired elastogenesis (PMID: 23954411)
2. Central nervous system: Mitochondrial dysfunction and impaired proline metabolism lead to progressive neurodegeneration, white matter reduction, and corpus callosum hypoplasia
3. Lens: Proline deficiency may contribute to cataract formation through impaired lens protein synthesis and oxidative stress
4. Vasculature: Impaired collagen/elastin in vessel walls leads to vascular tortuosity (PMID: 28757335)

GO Terms for Biological Processes

• GO:0006561 — proline biosynthetic process
• GO:0006560 — proline metabolic process
• GO:0006592 — ornithine biosynthetic process
• GO:0042450 — arginine biosynthetic process via ornithine
• GO:0000050 — urea cycle
• GO:0045454 — cell redox homeostasis
• GO:0030199 — collagen fibril organization
• GO:0007585 — respiratory gaseous exchange

CL Terms for Cell Types

• CL:0000057 — fibroblast (primary producer of ECM components)
• CL:0000540 — neuron (affected by proline metabolism disruption)
• CL:0002553 — fibroblast of skin (directly affected in cutis laxa)
• CL:0000115 — endothelial cell (affected in vascular tortuosity)
• CL:0002224 — lens epithelial cell (cataract formation)

7. Anatomical Structures Affected

Organ Level

Primary organs: - Skin (UBERON:0002097): Cutis laxa, wrinkled and inelastic skin, progeroid appearance - Brain (UBERON:0000955): Microcephaly, corpus callosum hypoplasia, white matter reduction, developmental delay - Eyes/Lens (UBERON:0000965): Bilateral cataracts, corneal clouding - Musculoskeletal system (UBERON:0002204): Joint laxity, hypotonia, contractures, hip dislocation

Secondary organs: - Cardiovascular system (UBERON:0004535): Intracranial vascular tortuosity - Skeletal system (UBERON:0001434): Growth restriction, rickets-like changes

Body systems involved: Integumentary, nervous (central), musculoskeletal, ophthalmological, cardiovascular (vascular), endocrine/metabolic

Tissue and Cell Level

• Connective tissue (UBERON:0002384): Defective elastic fiber and collagen assembly
• Neural tissue (UBERON:0003714): White matter and corpus callosum affected
• Lens epithelium (UBERON:0001803): Cataract formation
• Vascular endothelium (UBERON:0004852): Vessel wall defects leading to tortuosity

Subcellular Level

• Mitochondria (GO:0005739): Primary site of P5CS enzyme activity
• Mitochondrial matrix (GO:0005759): Location of P5CS enzyme
• Endoplasmic reticulum (GO:0005783): Site of collagen synthesis (affected secondarily)
• Extracellular matrix (GO:0031012): Defective collagen and elastic fiber deposition

Localization

Bilateral, symmetric involvement of skin, brain (corpus callosum, white matter), eyes, joints, and intracranial vasculature.

8. Temporal Development

Onset

• Typical age of onset: Congenital to early infantile (HPO: HP:0003577 — Congenital onset)
• Onset pattern: Insidious prenatal onset (IUGR detectable in utero), with progressive manifestation of neurological features in infancy
• Many features present at birth (IUGR, dysmorphic features, skin changes); motor and cognitive delays become apparent by infancy; cataracts may be congenital or develop in early infancy

Progression

• Disease course: Chronic, lifelong, with variable progression
• Skin findings: Present at birth, generally stable after infancy
• Developmental delay: Progressive gap compared to age-matched peers
• Neuroimaging: White matter changes may progress over time—T2 signal intensity increased "over time" (PMID: 28757335)
• Cataracts: May progress and require surgical intervention
• Growth: Persistent short stature throughout life
• Disease duration: Chronic, lifelong; no spontaneous remission

Critical Periods

• Prenatal period: IUGR indicates in utero impact on growth
• First 2 years of life: Window when developmental delay becomes apparent and early intervention is most beneficial
• Early childhood: Assessment for cataracts and skeletal management

9. Inheritance and Population

Epidemiology

• Prevalence: < 1 per 1,000,000 individuals — "It is an exceptionally rare condition, with an estimated prevalence of < 1 in 1,000,000 individuals" (PMID: 40018427)
• Incidence: Unknown; fewer than 20 cases reported worldwide as of 2025
• The condition is likely underdiagnosed due to phenotypic overlap with other cutis laxa subtypes

Genetic Inheritance

• Inheritance pattern: Autosomal dominant (de novo)
• Penetrance: Complete (all individuals with pathogenic variants are clinically affected)
• Expressivity: Variable — some intrafamilial variability in severity noted in SPG9A families (PMID: 33573605)
• Genetic anticipation: Not reported
• Germline mosaicism: Possible; one SPG9A family showed evidence consistent with de novo occurrence or gonadal mosaicism (PMID: 33573605)
• Founder effects: None; mutations arise de novo in each family
• Consanguinity: Not relevant (dominant de novo condition)
• Carrier frequency: Not applicable

Population Demographics

• Affected populations: No ethnic or racial predilection. Cases reported from European (Dutch, Finnish, German, Danish), Middle Eastern (Emirati, Algerian), South Asian (Indian), East Asian (Japanese), and North American backgrounds
• Geographic distribution: Worldwide, no geographic clustering
• Sex ratio: Approximately equal (both sexes affected)
• Age distribution: Most cases diagnosed in infancy/early childhood (typically before age 3)

10. Diagnostics

Clinical Tests

Laboratory Tests

• Plasma amino acid analysis: May show hypoprolinemia, hypoornithinemia, hypocitrullinemia, hypoargininemia — though amino acid levels may be normal in some patients (PMID: 29754261)
• Blood ammonia: May be elevated due to urea cycle disruption (first described in recessive P5CS deficiency; PMID: 11092761)
• Vitamin D levels: Should be checked as deficiency can compound skeletal features (PMID: 40018427)

Biomarkers

• Reduced plasma citrulline: The most consistent biochemical finding across ALDH18A1-related disorders (PMID: 33573605)
• Glutamine loading test: Can confirm metabolic block at P5CS level in fibroblasts

Imaging Studies

• Brain MRI: May show corpus callosum hypoplasia, reduced white matter volume, widened ventricles/extra-axial CSF spaces, wide perivascular spaces, increased T2 signal in white matter (PMID: 28757335)
• MR angiography: May reveal intracranial arterial and venous tortuosity
• Skeletal radiographs: May show rickets-like changes, osteopenia
• Hip ultrasound/X-ray: Developmental dysplasia of the hip

Ophthalmological Examination

• Slit lamp examination: Bilateral subcapsular cataracts
• Dilated fundus examination: To assess additional eye findings

Skin Biopsy

• Histopathology may show fragmented and reduced elastic fibers in the dermis; electron microscopy can demonstrate abnormal elastic fiber morphology

Genetic Testing

Recommended approach: 1. First-tier: Whole exome sequencing (WES) or targeted gene panel including connective tissue disorder genes 2. Confirmatory: Sanger sequencing of ALDH18A1 to confirm the variant 3. Parental testing: To confirm de novo origin

MAXO terms: - MAXO:0000127 — genetic testing - MAXO:0009006 — whole exome sequencing

Differential Diagnosis

Screening

• Newborn screening: Not available; too rare and no suitable biomarker
• Prenatal testing: Available if familial variant is known
• Cascade screening: Not typically applicable given de novo nature

11. Outcome/Prognosis

Survival and Mortality

• Life expectancy: Not well established due to rarity; patients appear to survive into childhood and beyond
• Mortality rate: Unknown; no systematic survival data exist
• Disease-specific mortality: Unknown but likely influenced by neurological complications

Morbidity and Function

• Morbidity: High; most patients have significant motor and cognitive disability
• Disability outcomes: Severe intellectual disability in most cases; delayed or absent independent ambulation; visual impairment from cataracts; dependency on caregivers
• Quality of life: Severely reduced; no formal QoL measurements available

Disease Course

• Complications: Progressive cataracts, recurrent joint dislocations, feeding difficulties and failure to thrive, possible seizures, risk of complications from vascular tortuosity
• Recovery potential: Limited; the underlying metabolic defect is permanent. Supportive care can improve functional outcomes.

Prognostic Factors

• Mutation location: G5K domain variants associated with more severe metabolic phenotype
• Early intervention: Physical therapy and developmental support may improve outcomes
• No formal prognostic biomarkers have been identified

12. Treatment

Overview

There is no curative treatment for ADCL3. Management is entirely supportive, multidisciplinary, and symptomatic.

Pharmacotherapy

• No disease-modifying drugs are available
• Proline supplementation: Theoretically rational but not systematically studied in ADCL3 (MAXO:0001298 — dietary supplement therapy)
• Vitamin D supplementation: When deficiency documented (PMID: 40018427)
• Antiepileptic drugs: For seizure management when present (MAXO:0000756)

Surgical and Interventional

• Cataract surgery: For visually significant cataracts (MAXO:0000571)
• Orthopedic surgery: For hip dislocation and joint instability (MAXO:0000002)

Supportive and Rehabilitative

Experimental/Potential Future Therapies

• Gene therapy: Not currently in development; the dominant-negative mechanism poses a therapeutic challenge, as gene augmentation alone would not suffice — allele-specific silencing of the mutant allele would be required
• Allele-specific antisense oligonucleotides (ASOs): Targeting the mutant ALDH18A1 allele
• CRISPR-based correction: Of the de novo mutation
• Substrate supplementation: Proline, ornithine, arginine — rationale exists but no clinical trials
• Sodium L-ascorbate: Has been shown to enhance elastic fiber deposition by fibroblasts (PMID: 25015208); theoretical benefit but untested in ADCL3
• No clinical trials registered on ClinicalTrials.gov specifically for ADCL3 as of 2025

13. Prevention

Primary Prevention

Not feasible. As a de novo genetic condition, primary prevention is not possible. No modifiable risk factors are known.

Secondary Prevention (Early Detection)

• Prenatal: IUGR detection on routine obstetric ultrasound may raise suspicion
• Neonatal: Clinical recognition of cutis laxa phenotype followed by genetic testing enables early diagnosis
• Cascade screening: Not applicable for de novo cases; parental testing to exclude low-level mosaicism is recommended

Tertiary Prevention (Complication Prevention)

• Regular ophthalmological examinations to detect and treat cataracts early
• Developmental screening and early intervention programs
• Hip surveillance to prevent/manage dislocation
• Neuroimaging monitoring for progressive white matter changes
• Nutritional monitoring for growth optimization

Genetic Counseling

• Recurrence risk: Very low (~1%) if parental germline mosaicism cannot be excluded
• Prenatal testing: Available if specific mutation is known
• Preimplantation genetic diagnosis (PGD): Technically feasible
• MAXO term: MAXO:0000079 (genetic counseling)

14. Other Species / Natural Disease

Natural Disease in Animals

No naturally occurring animal model of ADCL3 has been reported. Cutis laxa has been reported in some animal breeds but not linked to ALDH18A1 orthologs.

Orthologous Genes

Evolutionary Conservation

The ALDH18A1 gene and P5CS enzyme are highly conserved across eukaryotes. The Arg138 residue affected in ADCL3 is "highly conserved" across all phyla (PMID: 26320891). Similarly, the H784 residue affected in autosomal recessive cutis laxa "is invariant across all phyla and lies within a previously unrecognised, conserved C-terminal motif in P5CS" (PMID: 18478038).

The proline biosynthetic pathway is critically important across species — in trypanosomatids, proline metabolism is essential for energy production and parasite differentiation (PMID: 39960766; PMID: 23894476).

Zoonotic Potential

Not applicable. ADCL3 is a genetic disease and cannot be transmitted between species.

15. Model Organisms

Mouse Models

Pycr1 and Pycr2 knockout mice have been studied as models for proline biosynthesis disorders (PMID: 33734376):

• Pycr1 null mice: Did not show integument or cutis laxa phenotypes
• Pycr2 mutant mice: Showed neurological features (weight loss, kyphosis, hind-limb clasping) and severe loss of subcutaneous fat, but "primary features such as elastin abnormalities were not observed"
• Pycr1;Pycr2 double mutants: "Sub-viable and unhealthy compared to either single mutant, indicating the genes are largely functionally redundant"
• Proline-free diet worsened Pycr2 mutant phenotype, demonstrating "Pycr1 and -2 have redundant functions in proline biosynthesis, and their loss makes proline a semi-essential amino acid"

Model Characteristics

Model Limitations

• No specific Aldh18a1 dominant-negative knock-in mouse model has been published for ADCL3
• Pycr models address downstream steps in proline biosynthesis but not the P5CS-specific dominant-negative mechanism
• Species differences in proline metabolism and skin structure may limit translational value

Recommended Model Development

1. Knock-in mouse: Aldh18a1 p.Arg138Trp heterozygous knock-in would be the most relevant model
2. Zebrafish models: Rapid screening platform for P5CS deficiency phenotypes
3. Patient-derived iPSCs: Differentiated into fibroblasts, neurons, and other affected cell types
4. Organoids: Skin and brain organoids from patient iPSCs for tissue-specific pathology

Resources

• MGI (Mouse Genome Informatics): Aldh18a1 MGI:1888908
• ZFIN: aldh18a1
• IMPC (International Mouse Phenotyping Consortium): Data available for Aldh18a1

Key Findings

Finding 1: ADCL3 is caused by de novo heterozygous dominant-negative mutations in ALDH18A1

Eight unrelated individuals with de novo heterozygous missense mutations in ALDH18A1 at residue Arg138 (p.Arg138Trp, p.Arg138Gln, p.Arg138Gly) were identified in the landmark 2015 study. The mutational spectrum has since expanded to include p.Arg126His (PMID: 28228640) and p.Ser134Pro (PMID: 40164711). All reported variants are de novo, cluster in the G5K domain, and exert dominant-negative effects.

Finding 2: The dominant-negative mechanism disrupts P5CS oligomeric complex and sub-mitochondrial distribution

Functional studies using patient fibroblasts and heterologous overexpression demonstrated that the mutant P5CS protein is stable, interacts with wild-type P5CS, but disrupts the oligomeric complex (reduced size on native gel) and shows altered sub-mitochondrial distribution, leading to reduced enzymatic activity and delayed proline accumulation (PMID: 26320891).

Finding 3: ADCL3 has a distinctive multisystem phenotype

The clinical phenotype includes progeroid cutis laxa, IUGR, postnatal growth restriction, global developmental delay, microcephaly, cataracts, hypotonia, joint laxity, hip dislocation, and intracranial vascular tortuosity. This constellation is distinct from other cutis laxa subtypes and progeroid syndromes.

Finding 4: P5CS is a bifunctional enzyme critical for proline/ornithine biosynthesis

P5CS catalyzes the conversion of glutamate to delta-1-pyrroline-5-carboxylate, a critical step in the biosynthesis of proline, ornithine, and arginine (PMID: 11092761). Impairment of this pathway explains both the connective tissue (proline-dependent) and metabolic (ornithine/urea cycle) aspects of the disease.

Finding 5: Neuroimaging reveals characteristic vascular and white matter abnormalities

Intracranial arterial and venous tortuosity, widened CSF spaces, and progressive white matter signal abnormalities provide neuroimaging signatures that can aid diagnosis (PMID: 28757335).

Finding 6: ALDH18A1 mutations cause a four-disease phenotypic spectrum

ADCL3, ARCL3A, SPG9A, and SPG9B represent a continuum of P5CS deficiency with neurodegeneration as a shared feature (PMID: 32798076). The specific clinical presentation depends on inheritance pattern and mutation location.

Finding 7: Domain-specific genotype-phenotype correlations exist

G5K domain mutations cause reduced plasma proline, citrulline, and arginine, while G5PR domain mutations may not affect amino acid levels (PMID: 29754261). This has diagnostic and potentially therapeutic implications.

Mechanistic Model

    ALDH18A1 De Novo Missense Mutation (G5K Domain)
                        │
                        ▼
    Mutant P5CS Protein (Stable, Misfolded G5K Domain)
                        │
          ┌─────────────┴─────────────┐
          ▼                           ▼
      Incorporates into                Altered Sub-mitochondrial
      WT P5CS Oligomers                    Distribution
          │                           │
          └─────────────┬─────────────┘
                        │
                        ▼
          DOMINANT-NEGATIVE EFFECT
    Reduced P5CS Enzymatic Activity
                        │
    ┌───────────────────┼───────────────────┐
    ▼                   ▼                   ▼
    ↓ Proline              ↓ Ornithine         ↓ Mitochondrial
    Biosynthesis           Biosynthesis         Redox Balance
    │                   │                   │
    ▼                   ▼                   ▼
    ↓ Collagen/            ↓ Citrulline/       Oxidative
    Elastin Synthesis      Arginine             Stress
    │                   │                   │
  ┌────────┼────────┐     ┌────┴─────┐            │
  ▼        ▼        ▼     ▼          ▼            ▼
       CUTIS    VASCULAR   JOINT  UREA      GROWTH    NEURO-
       LAXA     TORTUOSITY LAXITY CYCLE     RESTRICT. DEGENERATION
                  IMPACT
  │        │        │        │         │          │
  └────────┴────────┴────────┴─────────┴──────────┘
                    │
                    ▼
        ADCL3 CLINICAL PHENOTYPE
      (Progeroid appearance, developmental delay,
       cataracts, microcephaly, hypotonia)

Evidence Base

Key Publications

Limitations and Knowledge Gaps

1. Extreme rarity: Fewer than 20 cases reported worldwide; all data come from individual case reports and small case series, limiting statistical power and generalizability.

2. No natural history studies: The long-term prognosis, life expectancy, and disease trajectory beyond childhood remain unknown.

3. Incomplete genotype-phenotype correlation: With only three mutational hotspots characterized (Arg138, Arg126, Ser134), it is unclear whether other G5K domain variants could cause ADCL3 and whether phenotypic severity correlates with specific residues.

4. Variable amino acid data: Plasma amino acid levels are variably reported and may not always be abnormal, complicating biochemical diagnosis.

5. No animal model with the specific dominant-negative mechanism: Existing mouse models address downstream proline biosynthesis (Pycr1/2) but not the P5CS dominant-negative effect central to ADCL3.

6. No therapeutic trials: Treatment is entirely supportive; no interventional studies (even amino acid supplementation) have been conducted.

7. Limited neuroimaging: Only a handful of patients have had detailed neuroimaging; the full spectrum of CNS involvement is likely undercharacterized.

8. No quality-of-life data: No standardized QoL assessments have been performed in ADCL3 patients.

9. No molecular profiling: No transcriptomic, proteomic, or metabolomic studies have been published on ADCL3 patient tissues beyond basic amino acid levels.

10. Diagnostic delay: Phenotypic overlap with other cutis laxa subtypes and progeroid syndromes likely leads to diagnostic delay and under-ascertainment.

Proposed Follow-up Experiments/Actions

High Priority

1. Establish an international ADCL3 patient registry to collect natural history data, standardize phenotyping, and facilitate collaborative research.

2. Generate a knock-in mouse model (e.g., Aldh18a1-p.Arg138Trp heterozygous knock-in) to study the dominant-negative mechanism in vivo and test therapeutic interventions.

3. Conduct a proline/ornithine supplementation pilot study in a compassionate-use framework, monitoring plasma amino acid levels, growth parameters, and developmental outcomes.

4. Perform fibroblast-based multi-omics profiling (transcriptomics, metabolomics, proteomics) comparing ADCL3 patient fibroblasts to controls to comprehensively characterize metabolic disruptions.

Medium Priority

1. Develop allele-specific ASOs targeting the common Arg138 mutant alleles, leveraging single-nucleotide specificity required for dominant-negative disorders.

2. Systematic longitudinal neuroimaging study with MRI/MRA in all known ADCL3 patients to characterize the natural history of white matter and vascular changes.

3. Generate iPSC-derived neuronal and connective tissue models from ADCL3 patient fibroblasts to study cell-type-specific pathology.

Lower Priority

1. CRISPR-based gene correction in patient iPSCs as proof-of-concept for future therapeutic development.

2. Investigate whether sodium L-ascorbate (PMID: 25015208) enhances elastic fiber production in ADCL3 fibroblasts in vitro.

3. Cross-species functional studies in yeast or Drosophila P5CS orthologs to systematically map the impact of ADCL3-equivalent mutations on enzyme function and oligomerization.

Report generated: 2026-05-05. Based on systematic review of 40 publications and publicly available disease databases. This report covers a disease with fewer than 20 known cases worldwide; all assertions should be interpreted in the context of extremely limited evidence.